Accelerate Diagnostics (NASDAQ:AXDX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX) in a report issued on Sunday morning. The brokerage issued a hold rating on the medical research company’s stock.

Separately, BTIG Research raised shares of Accelerate Diagnostics to a “strong-buy” rating in a report on Wednesday, December 11th.

Accelerate Diagnostics Stock Performance

Accelerate Diagnostics stock opened at $1.08 on Friday. Accelerate Diagnostics has a 52 week low of $0.73 and a 52 week high of $3.05. The firm has a market cap of $27.05 million, a P/E ratio of -0.38 and a beta of 0.59. The business’s fifty day moving average is $1.47 and its two-hundred day moving average is $1.54.

Insider Transactions at Accelerate Diagnostics

In related news, Director John Patience bought 200,000 shares of Accelerate Diagnostics stock in a transaction on Tuesday, December 3rd. The shares were purchased at an average price of $1.57 per share, for a total transaction of $314,000.00. Following the completion of the acquisition, the director now owns 653,224 shares in the company, valued at approximately $1,025,561.68. This represents a 44.13 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 43.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Accelerate Diagnostics stock. Y Intercept Hong Kong Ltd purchased a new position in shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 19,866 shares of the medical research company’s stock, valued at approximately $34,000. Y Intercept Hong Kong Ltd owned approximately 0.08% of Accelerate Diagnostics as of its most recent SEC filing. Institutional investors own 17.14% of the company’s stock.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.